Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Medulloblastoma 1Ependymoma 1

Interventions

Specimen Handling 18Cyclophosphamide 17Magnetic Resonance Spectroscopy 16Dexamethasone 15Cisplatin 14Vincristine 13Radiotherapy 13Radiation 11Etoposide 10Carboplatin 10durvalumab 9Radiotherapy, Intensity-Modulated 9Paclitaxel 9Doxorubicin 8Cytarabine 8Temozolomide 7Rituximab 7Prednisone 7Lenalidomide 7Irinotecan 7Gemcitabine 7Fluorouracil 7Docetaxel 7Bortezomib 7Biopsy 7daratumumab 6Platinum 6Leucovorin 6Capecitabine 6tremelimumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × NETWORK × Histamine Antagonists × Clear all
NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Pediatric Brain Tumor Consortium

Phase 2 Active not recruiting
62 enrolled
CNS

Ependymoma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡